evenfolio

Healthcare · NSE: SHILPAMED

Shilpa Medicare

Q2 FY27 earnings and concall highlights

Price as of 16 Nov 2026
938.35−5.36%

Q2 FY27 earnings call · Guided by management

Call held 5 Nov 2026 · Read the filing on NSEFiling

4​programsNCE CDMO programs to commercialise · CDMO · next 18 to 24 monthsBhutada · p. 3
15–0​productsNew oncology generic products completed · API · FY27Bhutada · p. 3
₹252​CrCapex spent · H1 FY27Dalal · p. 5
1–0​programsLate-stage CDMO programs commercialised · CDMO · next yearBhutada · Q&A · p. 8
M.Cap
₹18,352Cr
P/E
55.2×
1Y return
+147.19%
From 52W high
−14.3%

Highlights are read by AI from the company's filing and can contain mistakes. Check the source page linked to each line.

Share price

Results Q2 FY27, as filed · consolidated · ₹ Cr

Q2 FY27Q2 FY26YoYQ1 FY27QoQ
Revenue529370+43.0%466+13.6%
EBITDA142108+31.5%136+4.5%
EBITDA margin26.9%29.3%-236 bps29.3%-234 bps
One-off items-1————
PBTProfit before tax10465+60.4%92+12.4%
Net profit7944+79.7%101-21.5%
EPS (₹)4.052.25+80.0%5.16-21.5%

From the company's own results filing on NSE. Net profit is the owners' share. Growth and the dotted lines are worked out from the filed figures.

Guidance

ROCE expected to improve further in coming quarters

Alpesh Dalal · Chief Financial Officer · p. 5
“And with improvement in business mix and higher operating leverage, we expect ROCE to improve further in the coming quarters.”

More figures from the call

Peptides · Capacity
2​linesPeptide manufacturing lines added
“Today, we have 4 manufacturing lines in peptides, and we are adding an additional 2 manufacturing lines.”
Keshav Bhutada · Executive Director and Chief Executive Officer · Q&Ap. 6
Formulation · Acquisitions and new business
5–0​productsComplex 505(b)(2) products in advanced development · next 2 to 3 years
“we have 5-plus complex 505(b)(2)s under advanced stages of development, which we will be commercializing in the next 2 to 3 years.”
Keshav Bhutada · Executive Director and Chief Executive Officerp. 4
Biologics CDMO · Segments
3​programsCDMO biologics programs with Phase I supplies completed · FY27
“We currently have 6-plus active CDMO biologics programs, in which Phase I supplies for 3 CDMO biologics programs for our clients will be completed in FY '27.”
Keshav Bhutada · Executive Director and Chief Executive Officerp. 4
CDMO · Segments
3​programsLate-stage CDMO programs where company supplies API
“And each of them is a very significant opportunity for us because, of the total 4 programs, in 3 of the programs, we are supplying API to our end customers, which will be a big part of the overall purchasing for the product.”
Keshav Bhutada · Executive Director and Chief Executive Officer · Q&Ap. 8

In short

  1. 01Q2 revenue was Rs 538 crore, up 35%, the highest quarter so far.
  2. 02Q2 EBITDA was Rs 151 crore, up 37%; H1 EBITDA margin was 29%.
  3. 03Large peptide capacity to be commissioned by end of FY27; 2 peptide lines being added to 4.
  4. 04Of 4 late-stage CDMO programs, at least 1 expected to commercialise next year and 3 the year after.
  5. 05Enzalutamide, Abraxane and Rotigotine launches on track for FY28; Rotigotine delayed by about 2 quarters.
  6. 06Net debt Rs 612 crore; H1 capex Rs 252 crore funded mainly by internal accruals.
  7. 07Gross margin fell due to higher API share and higher global raw material costs.
  8. 08Management does not give revenue or forward guidance.

Capex

API: Large integrated peptide manufacturing capacity to be commissioned by end of FY27

Keshav Bhutada · Executive Director and Chief Executive Officer · p. 3
“On the capex front, we are on track to commission one of the largest integrated peptide manufacturing capacities by the end of FY '27.”

Peptides: Peptide investment is phased; more spend depends on current capacity use

Keshav Bhutada · Executive Director and Chief Executive Officer · Q&A · p. 9
“If we have good utilization there, then further investments will be planned.”

Capacity

Peptides: New peptide capacity can make peptides at tonnage scale a year

Keshav Bhutada · Executive Director and Chief Executive Officer · Q&A · p. 6
“See, the manufacturing capacity we are building can manufacture peptides at a tonnage scale in yearly volume.”

Peptides: Peptide capacity is for a mix of CDMO, GLP-1 and HPAPI

Keshav Bhutada · Executive Director and Chief Executive Officer · Q&A · p. 7
“I think the peptide capacity we are building is for a mix of CDMO, GLP-1 and HPAPI.”

Order book

Peptides: No peptide orders in hand yet; capacity planned on customer indications

Keshav Bhutada · Executive Director and Chief Executive Officer · Q&A · p. 7
“I did not say that we already have orders in hand. But yes, there is an indication from the customers based on which we have planned this capacity.”

Segments

Focus to stay on high gross margin businesses: peptides, oncology APIs and CDMO

Keshav Bhutada · Executive Director and Chief Executive Officer · p. 3
“And going forward, our focus will continue to remain on high gross margin businesses, mainly peptides, oncology APIs and CDMO.”

API: API had highest ever quarterly revenue; momentum expected to continue

Keshav Bhutada · Executive Director and Chief Executive Officer · p. 3
“In API, I'm happy to inform you that we delivered the highest ever quarterly revenue in our history, and we remain confident of continuing this momentum in the upcoming quarters.”

Formulation India: India formulation business grew 2.5x in H1, led by Nor-UDCA

Keshav Bhutada · Executive Director and Chief Executive Officer · p. 4
“Our India business grew 2.5x in H1 on a Y-o-Y basis, led by Nor-UDCA, a novel first-in-class treatment for NAFLD.”

Biologics: Biologics is 12% of revenue, with a portfolio of 7 biosimilars

Keshav Bhutada · Executive Director and Chief Executive Officer · p. 4
“It contributes 12% of our revenue today, with a portfolio of 7 biosimilars whose molecules have average global sales of more than USD10 billion.”

Non-captive API: Non-captive API revenue Rs 255 crore in Q2, up 24%

Alpesh Dalal · Chief Financial Officer · p. 5
“Our non-captive API business clocked a revenue of INR255 crores for the quarter, growing at 24% year-on-year”

Demand

Peptides: Visibility on some peptide programs needing volumes; capacity planned accordingly

Keshav Bhutada · Executive Director and Chief Executive Officer · Q&A · p. 7
“But we have visibility on some programs where we are confident that there will be a requirement for some volumes.”

Business momentum expected to continue into H2

Alpesh Dalal · Chief Financial Officer · Q&A · p. 12
“But the way we are seeing the business, it has good traction, and we expect the momentum to continue.”

Margins and costs

Gross margin dipped as higher-margin formulation share fell against strong API

Keshav Bhutada · Executive Director and Chief Executive Officer · Q&A · p. 6
“And when you compare API to the formulation business, the gross margins in the formulation business are much higher. That has led to a small decline in the gross margin.”

API: API raw material costs up globally; pressure to last until prices settle

Keshav Bhutada · Executive Director and Chief Executive Officer · Q&A · p. 12
“And in API, raw material costs have gone up globally. So until raw material prices settle down, this will continue.”

Licensing income has no COGS but carries R&D and other expenses

Alpesh Dalal · Chief Financial Officer · Q&A · p. 12
“So to that extent, it doesn't have any COGS, but it does have certain expenses which are sitting in R&D and other expenses.”

Debt and working capital

Net debt at Rs 612 crore, stable despite higher capex

Alpesh Dalal · Chief Financial Officer · p. 5
“Our net debt stands at INR612 crores, which has remained stable despite a significant increase in the capex program.”

Acquisitions and new business

Formulation: Nor-UDCA being extended into additional indications

Keshav Bhutada · Executive Director and Chief Executive Officer · p. 4
“We are also working on extending this product into additional indications, which will help us grow this product in the years to come.”

Formulation: Enzalutamide, Abraxane and Rotigotine patch launches on track for FY28

Keshav Bhutada · Executive Director and Chief Executive Officer · p. 4
“Three important upcoming launches, Enzalutamide, Abraxane and the Rotigotine patch, are on track for FY '28”

Formulation: Semaglutide GLP-1 injectable exhibit batches done; Europe and RoW filing on track

Keshav Bhutada · Executive Director and Chief Executive Officer · p. 4
“In the current quarter, we have completed the semaglutide GLP-1 injectable exhibit batches, and we are on track to submit in Europe and RoW markets.”

Formulation: Complex transdermal patch for Europe: exhibit batches done, filing planned in FY28

Keshav Bhutada · Executive Director and Chief Executive Officer · p. 4
“we have completed exhibit batches in the current quarter, and we are planning to file this product in FY '28.”

Partner Unicycive filed NDA with additional site; revised PDUFA date March 2027

Keshav Bhutada · Executive Director and Chief Executive Officer · p. 4
“our partner has already filed the NDA with one additional site, and has received a revised PDUFA date of March 2027.”

Risks

Jadcherla US FDA remediation ongoing; no impact seen on 2-3 year plan

Keshav Bhutada · Executive Director and Chief Executive Officer · Q&A · p. 11
“we are working with the U.S. FDA on the remediation measures. But that doesn't have any impact on our revenues or on our business plan for the next 2 to 3 years.”

Jadcherla plant reinspected and cleared again by EU authorities

Alpesh Dalal · Chief Financial Officer · Q&A · p. 11
“Recently, the plant was reinspected by the EU authorities and they have cleared it again.”

Most critical US filings moved to alternate CMO partner sites

Alpesh Dalal · Chief Financial Officer · Q&A · p. 11
“As far as the U.S. business is concerned, we have moved most of our critical filings to alternate sites with our CMO partners.”

Formulation: Rotigotine launch delayed about 2 quarters by EU raw material approval; now H1 next year

Keshav Bhutada · Executive Director and Chief Executive Officer · Q&A · p. 11
“And the main reason was that there was one variation approval with the European agency for one of the raw materials, which took us an additional 2 quarters, but it is set to launch in the first half of next year.”

Formulation: No big change in numbers seen from Nilotinib generic competition

Keshav Bhutada · Executive Director and Chief Executive Officer · Q&A · p. 13
“So we don't currently see any big change in numbers because of Nilotinib generic competition.”

Other

Management says the years of investing ahead of revenue are behind the company

Keshav Bhutada · Executive Director and Chief Executive Officer · p. 3
“the years of investing ahead of revenue, are behind us. The years of harvesting are beginning.”

Q2 revenue was Rs 538 crore, up 35% year-on-year, highest ever

Alpesh Dalal · Chief Financial Officer · p. 5
“I'm pleased to report that we have delivered our highest ever quarterly revenues of INR538 crores, reflecting a robust growth of 35% year-on-year.”

H1 FY27 revenue was Rs 1,007 crore, up 44% year-on-year

Alpesh Dalal · Chief Financial Officer · p. 5
“And revenue for the first half was INR1,007 crores, growing at 44% year-on-year.”

Management aims to monetise all its investments

Keshav Bhutada · Executive Director and Chief Executive Officer · p. 5
“And we, as a company, remain confident of monetizing all our investments.”

Q2 EBITDA was Rs 151 crore, up 37%, highest ever

Alpesh Dalal · Chief Financial Officer · p. 5
“Alongside record revenue, we also reported our highest ever quarterly EBITDA at INR151 crores, up 37%”

Sources

Management's own statements, quoted from its NSE filings. This page was read by AI and can contain mistakes: check the source pages before relying on any figure. No forecast or opinion of ours. Not investment advice.

Search

Search funds, ETFs, stocks, pages and tools